Answers are grounded in this paper and cite their sources.
Limb ischemia is a severe manifestation of peripheral arterial disease with limited therapeutic options. Induction of therapeutic angiogenesis represents a promising strategy to restore blood perfusion. Natural bioactive compounds, particularly when integrated with biomaterial engineering, offer therapeutic potential with favorable biosafety profiles. Here, we demonstrate that catalpol (CTP), a bioactive compound from Rehmannia glutinosa, exerts pro-angiogenic effects by enhancing endothelial cell viability, proliferation, migration, and vascular sprouting in vitro. Catalpol upregulates angiogenesis-related markers and promotes angiogenesis via autophagy activation, which is validated using 3-methyladenine (3-MA). To improve local retention and sustained delivery, CTP-loaded silk fibroin nanoparticles (CTP/SFNP) are self-assembled via mild desolvation and incorporated into gelatin methacryloyl hydrogel (CTP/SFNP/GelMA). In a mouse hind limb ischemia model, this hydrogel promotes neovascularization, restores blood perfusion, alleviates tissue injury, and exhibits favorable biocompatibility. These findings highlight the therapeutic potential of CTP/SFNP/GelMA for ischemic diseases and identify autophagy activation as a potential mechanism underlying catalpol-mediated angiogenesis, providing insights into nanocarrier design for natural bioactive compounds.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: